​

X4 Pharmaceuticals (XFOR) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

XFOR Stock Forecast

X4 Pharmaceuticals (XFOR) stock forecast, based on 13 Wall Street analysts, predicts a 12-month average price target of $11.67, with a high of $12.00 and a low of $11.00. This represents a 203.12% increase from the last price of $3.85.

- $3 $6 $9 $12 $15 High: $12 Avg: $11.67 Low: $11 Last Closed Price: $3.85

XFOR Stock Rating

X4 Pharmaceuticals stock's rating consensus is Buy, based on 13 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 12 Buy (92.31%), 1 Hold (7.69%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 13 1 12 0 Strong Sell Sell Hold Buy Strong Buy

XFOR Price Target Upside V Benchmarks

TypeNameUpside
StockX4 Pharmaceuticals203.12%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts127
Avg Price Target$11.00$11.50$9.29
Last Closing Price$3.85$3.85$3.85
Upside/Downside185.71%198.70%141.30%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jul, 26-4---4
Jun, 26-3---3
May, 26-3---3
Apr, 26-3---3
Mar, 26-3---3
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jul 10, 2026Wells Fargo$11.00$3.96177.78%185.71%
Jun 02, 2026Thomas SmithLeerink Partners$12.00$4.11191.97%211.69%
Mar 09, 2026Guggenheim$12.00$4.15189.16%211.69%
Dec 05, 2025James CondulisStifel Nicolaus$10.00$3.80163.16%159.74%
Nov 05, 2025Stephen WilleyStifel Nicolaus$7.50$3.60108.33%94.81%
Aug 29, 2025Stephen WilleyStifel Nicolaus$9.00$3.87132.56%133.77%
Aug 13, 2025Swayampakula RamakanthH.C. Wainwright$3.50$2.5835.66%-9.09%
Dec 22, 2022Cantor Fitzgerald$3.00$0.85252.94%-22.08%
Dec 11, 2022Edward TenthoffPiper Sandler$3.00$0.93222.58%-22.08%
Nov 30, 2022H.C. Wainwright$5.00$1.85170.27%29.87%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Jul 10, 2026Wells FargoOverweightinitialise
Aug 13, 2025H.C. WainwrightBuyBuyhold
Jun 28, 2024H.C. WainwrightBuyBuyhold
Dec 22, 2022Cantor FitzgeraldOverweightinitialise
Dec 11, 2022Piper SandlerOverweightinitialise

Financial Forecast

EPS Forecast

$-20 $-15 $-10 $-5 $0 $5 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-17.10$-5.59$-1.87---
Avg Forecast$-0.61$-0.14$-0.56$-0.36$-0.05$0.01
High Forecast$-0.60$-0.12$-0.39$-0.28$0.26$0.01
Low Forecast$-0.63$-0.15$-0.74$-0.49$-0.28-
Surprise %2703.28%3892.86%233.93%---

Revenue Forecast

$0 $50M $100M $150M $200M $250M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported-$2.56M$35.11M---
Avg Forecast-$2.19M$21.55M$61.06M$142.21M$174.01M
High Forecast-$2.59M$28.42M$61.60M$144.03M$238.73M
Low Forecast-$1.96M$11.10M$60.52M$140.38M$85.73M
Surprise %-16.61%62.97%---

Net Income Forecast

$-150M $-110M $-70M $-30M $10M $50M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-101.17M$-37.45M$-79.20M---
Avg Forecast$-109.33M$-23.54M$-101.02M$-68.48M$-33.57M$1.78M
High Forecast$-106.74M$-21.26M$-69.61M$-49.97M$46.30M$2.64M
Low Forecast$-111.91M$-25.82M$-132.42M$-86.99M$-49.29M$605.45K
Surprise %-7.46%59.07%-21.60%---

XFOR Forecast FAQ

Is X4 Pharmaceuticals stock a buy?

X4 Pharmaceuticals stock has a consensus rating of Buy, based on 13 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 12 Buy, 1 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that X4 Pharmaceuticals is a favorable investment for most analysts.

What is X4 Pharmaceuticals's price target?

X4 Pharmaceuticals's price target, set by 13 Wall Street analysts, averages $11.67 over the next 12 months. The price target range spans from $11 at the low end to $12 at the high end, suggesting a potential 203.12% change from the previous closing price of $3.85.

How does X4 Pharmaceuticals stock forecast compare to its benchmarks?

X4 Pharmaceuticals's stock forecast shows a 203.12% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for X4 Pharmaceuticals over the past three months?

  • July 2026: 0% Strong Buy, 100.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • June 2026: 0% Strong Buy, 100.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • May 2026: 0% Strong Buy, 100.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is X4 Pharmaceuticals’s EPS forecast?

X4 Pharmaceuticals's average annual EPS forecast for its fiscal year ending in December 2026 is $-0.36, marking a -80.75% decrease from the reported $-1.87 in 2025. Estimates for the following years are $-0.05 in 2027, and $0.01 in 2028.

What is X4 Pharmaceuticals’s revenue forecast?

X4 Pharmaceuticals's average annual revenue forecast for its fiscal year ending in December 2026 is $61.06M, reflecting a 73.89% increase from the reported $35.11M in 2025. The forecast for 2027 is $142.21M, and $174.01M for 2028.

What is X4 Pharmaceuticals’s net income forecast?

X4 Pharmaceuticals's net income forecast for the fiscal year ending in December 2026 stands at $-68.484M, representing a -13.53% decrease from the reported $-79.199M in 2025. Projections indicate $-33.566M in 2027, and $1.78M in 2028.